Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Jun
17
Today In Oncology
Neoadjuvant Sacituzumab Govitecan in MIBC
Thyroid Cancer Reproductive Lifespan, Hormone Therapy Potentially Linked to Incidence
Two-Pronged Nudges Result in Timely Conversations Around Priorities of Cancer Care
MIBC Intravesical Recombinant BCG and Chemoimmunotherapy
Overall Survival Benefit With Ivonescimab Plus Chemotherapy in Advanced Squamous NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo